Please assess the completion status of the following clinical trial:

Trial Title: ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of SLE~* Active SLE~* On stable background therapy for 1 month~* Using highly effective contraception~Exclusion Criteria:~* Serious organ failure (renal functional impairment, severe central nervous system manifestations, severe heart failure, liver failure)~* Any clinical evidence of active chronic infection HIV, hepatitis B, hepatitis C~* Clinical significant pleuritis or pericarditis~* Type1 Diabetes and/or CROHN's disease~* Use of Benlysta (belimumab) in the past 4 weeks~* Use of Rituximab in the past 6 months~* Vaccination with live attenuated virus in the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ILT-101 (Type: EXPERIMENTAL): Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12

Based on this trial design, predict the completion outcome and termination type (if applicable).